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CFEX (Slc26a6) in rat kidneys, liver, and small intestine in an experimental model of 
oxalate nephrolitiasis
Dean Karaica1, Davorka Breljak1, Hrvoje Brzica1, Jovica Lončar2, Marija Ljubojević1, Carol M Herak-
Kramberger1, Vedran Micek1, Ivana Vrhovac1, Jana Ivković Dupor1, Ivan Mihaljević2, Petra Marić2,  
Tvrtko Smital2, Birgitta C. Burckhardt3, Gerhard Burckhardt3, and Ivan Sabolić1
Molecular Toxicology, Institute for Medical Research and Occupational Health1, Molecular Ecotoxicology, 
Division for Marine and Environmental Research, Rudjer Boskovic Institute2, Zagreb, Croatia, Physiology & 
Pathophysiology, University Medical Center, Göttingen, Germany3
CFEX (chloride/formate exchanger; Slc26a6) is an important anion exchanger of chloride, bicarbonate, oxalate (OX), 
formate, and hydroxyl ions in kidneys, liver, and the small intestine. Studies on CFEX-knockout mice indicated a possible 
role of CFEX in the development of hyperoxaluria and OX urolithiasis/nephrolithiasis, which in humans is more frequent 
in men. Here we studied the expression of the CFEX protein and mRNA in the organs of male and female rats, and 
employed a rat model of ethylene glycol (EG)-induced OX urolithiasis in order to correlate the expression of CFEX with 
sex-related hyperoxaluria. Rats drank EG in water (0.75 % vol/vol) or water (control) for 30 days. Tissue expressions of 
the CFEX protein and mRNA were analysed by immunochemical methods and qRT-PCR, respectively. The specificity 
of an anti-CFEX antibody, used in immunochemical studies, was confirmed in HEK293 cells transiently transfected with 
CFEX cDNA. In kidneys, the CFEX protein was immunolocalized to the proximal tubule brush-border membrane (BBM) 
with segmental (S3>>S1~S2) and sex (male>female) differences. Sex-unrelated expression was detected in the BBM of 
enterocytes (duodenum>jejunum) and in the hepatocyte canalicular membrane. In immunoblots, the CFEX protein band 
of ~120 kDa in various organs showed an expression pattern comparable to that in immunocytochemistry; however, renal 
CFEX mRNA expression was not sex-dependent. Compared to controls and EG-treated females, the EG-treated male rats 
exhibited hyperoxalemia, hyperoxaluria and OX crystaluria, but the expression of CFEX mRNA and protein remained 
unaffected in the organs of both sexes. Thus, basic CFEX expression in both rat sexes was sufficient for OX handling 
even upon EG-treatment, indicating that in rats, CFEX plays no major role in generating EG-induced hyperoxaluria and 
nephrolithiasis.
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Transporters as mediators of cisplatin effects and side-effects
Giuliano Ciarimboli1,2, Anna Hucke1,2, Rita Schröter1,2, Antoinette Am Zehnhoff-Dinnesen2,3,  
Claudia Lanvers4, Alex Sparreboom5, Jason Sprowl5, and Eberhard Schlatter1,2
Experimental Nephrology, Medical Clinic D1; Interdisciplinary Center for Clinical Research (IZKF)2, Department of 
Phoniatrics and Pedaudiology3, University Hospital Münster; Department of Pediatric Hematology and Oncology, 
University Children’s Hospital Münster4, Münster, Germany, Department of Pharmaceutical Sciences, St. Jude 
Children’s Research Hospital, Memphis, USA5
The use of the effective antineoplastic agent cisplatin is hampered by serious side effects, such as nephro-, oto-, and 
neurotoxicity. In this work, we studied whether organic cation transporters (OCT) mediate the uptake and hence the 
toxicities of cisplatin in vitro and in vivo. Interaction of cisplatin with the transport of the fluorescent cation 4-(4-(dimethyl-
amino)styril)-methylpyridinium (ASP+) was investigated in HEK293 cells stably transfected with hOCT1 or hOCT2 and 
in freshly isolated human hepatocyte and human proximal tubules. Cisplatin preferentially inhibited ASP+ transport via 
hOCT2. Incubation of hOCT2 cells with cisplatin induced apoptosis, which was completely suppressed by co-incubation 
by the hOCT2 substrate cimetidine. In vivo, the effects of cisplatin treatment on kidney and hearing (auditory brainstem 
response, ABR) functions were compared in wild type (WT) and OCT1/2 double knock-out (KO) mice. While in WT 
cisplatin led to reduced ABR and increased renal glucose, water, protein excretion and apoptosis, no sign of ototoxicity 
and only mild nephrotoxicity was observed after cisplatin treatment of KO mice. Co-medication of WT mice with cisplatin 
and cimetidine protected from ototoxicity and partly from nephrotoxicity. We also showed that OCT2 is expressed on 
hair cells of the cochlea and in dorsal root ganglia. Tumour-derived cell lines did not show a significant expression of 
mRNA for OCT2, suggesting that cisplatin uptake is mediated by other mechanisms here. These findings are very important 
for establishing chemotherapeutical protocols aimed at maximizing the antineoplastic effect of cisplatin, while reducing 
the risk of toxicities. Supported by IZKF Münster, Grant Cia2/013/13.
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Inhibitors of glucose transporter SGLT1 in the treatment of diabetes mellitus will not act 
only in the kidneys; the transporter is also present in other rodent and human organs
Ivana Vrhovac1, Davorka Breljak1, Dean Karaica1, Nikola Radović2, Ognjen Kraus3, Stipislav Jadrijević4, 
Hermann Koepsell5, and Ivan Sabolić1
Molecular Toxicology Unit, Institute for Medical Research and Occupational Health1, Urology, Clinical Hospitals 
Dubrava2 and Sisters of Mercy3, Department for Surgery of the Digestive Tract, Clinical Hospital Merkur4, Zagreb, 
Croatia; Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany5
Diabetes mellitus, one of the most common chronic diseases in population, is becoming a major health and economic 
problem. Current therapies with insulin and metformin, aimed at reducing blood glucose, are often ineffective and/
or problematic due to the induction of hypoglycemia, body weight gain, and occasional death resulting from 
cardiovascular disease. A novel generation of oral anti-diabetics inhibits sodium-D-glucose cotransporters in the 
small intestine (SGLT1/SLC5A1), thus diminishing the absorption of glucose from the diet, as well as in the kidneys 
(SGLT1 and/or SGLT2/SLC5A2), thus decreasing glucose reabsorption along the nephron and enhancing its excretion 
through urine. Overall, this improves glycemia, reduces body weight, lowers blood pressure, and decreases damage 
to the cardiovascular system. However, our recent studies showed that in humans, SGLT1 is not expressed only in 
the intestinal and renal epithelium; it was also detected in the liver (bile duct epithelium), lungs (bronchiolar Clara 
cells and alveolar type II cells), and heart (blood capillaries). These places represent possible targets for novel 
SGLT1 inhibitors. SGLT1 or dual (SGLT1+SGLT2) inhibitors may inhibit various SGLTs-related functions, such 
as fluid absorption in the lungs, energy supply to Clara cells, and glucose release from the heart capillaries, and 
may thus cause functional disorders. In addition, our novel unpublished data showed that in mice, Sglt1 is localized 
in the kidneys, small intestine, liver, pancreas, salivary glands, tongue, prostate, seminal vesicles, and uterus. The 
newly discovered localizations of SGLT1/Sglt1 suggest certain novel functions for this transporter, which could be 
of great physiological and biomedical importance.
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Genetic variability in organic cation transporters: pharmacology, pathophysiology,  
and beyond
Mladen V. Tzvetkov, Frank Faltraco, Nawar Dalila, Tina Seitz, Robert Stalmann, and Jürgen Brockmöller
Institute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany
Naturally occurring genetic variants substantially affect the expression and function of organic cation transporters. 
Therefore, these variants may lead to inter-individual variations in plasma and organ concentrations of endogenous 
molecules and drugs and may cause variations in drug pharmacokinetics, efficacy and toxicity, or may confer susceptibility 
to diseases. Common genetic variants causing loss of OCT1 activity have been shown to affect the hepatic uptake and 
pharmacokinetics of the drugs morphine, tramadol and tropisetron. On the other hand, genetic variants causing loss of 
OCT1 activity are suggested to modulate the efficacy of drugs acting in the liver, like metformin. Here we give an overview 
on the available data about the genetically-determined loss of OCT1 activity and discuss potential applications for 
personalised drug therapy. Furthermore, specific global patterns of loss of OCT1 activity were observed. We discuss how 
these patterns may confer inter-ethnical variability of pharmacokinetics and efficacy of clinically relevant drugs and how 
they may point to selection pressure for losing or maintaining OCT1 activity. In OCT2, the common polymorphism 
Ala270Ser was repeatedly reported to associate with inter-individual variability in metformin pharmacokinetics. We 
present meta-analyses of currently available studies showing the inconsistency and limited size of these effects. In contrast, 
polymorphisms in OCTN1 and OCTN2 were repeatedly reported as risk factors for Crohn’s disease. Meta-analyses of 
available studies are presented illustrating the high consistency of these observations. Finally we discuss the potential 
effects of regulatory polymorphisms in the MATE1 and MATE2K genes on the pharmacokinetics and efficacy of metformin.
KEY WORDS: Crohn’s disease; genetic polymorphisms; hepatic uptake; metformin; morphine; pharmacokinetics; renal 
clearance; SNPs; tramadol; tropisetron
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Age and sex differences in expression of P-glycoprotein (P-gp/Mdr1/Abcb1) in  
rat liver and kidneys
Jana Ivković Dupor1, Marija Ljubojević1, Davorka Breljak1, Ivana Vrhovac1, Dean Karaica1, Vedran Micek1, 
Carol M. Herak-Kramberger1, Roberto Antolović2, and Ivan Sabolić1
Molecular Toxicology Unit, Institute for Medical Research and Occupational Health, Zagreb1, Department of 
Biotechnology, University of Rijeka, Rijeka2, Croatia
P-glycoprotein (P-gp; ABCB1 in humans/Abcb1 in rodents) is an ATP-dependent multidrug efflux transporter in 
the cell membrane, also known as the multidrug resistant protein 1 (MDR1 in humans/Mdr1 in animals), constitutively 
expressed in the a) bile canaliculi of hepatocytes, b) brush-border membrane of the renal proximal tubule cells, c) 
luminal membrane of the intestinal enterocytes, d) blood-brain, blood-testis, and mother-foetus barriers, and e) 
hematopoietic cells. P-gp mediates the transport of some endogenous compounds and various xenobiotics (drugs, 
toxins, environmental organic compounds, and their metabolites) out of the cells, thus protecting the cell’s interior 
from the potentially toxic effects of these compounds. Although P-gp is a highly studied transporter in a variety of 
(patho)physiological conditions in human and animal organs, its age-dependent expression is still a controversial 
issue. Here, we investigated the ontogenic pattern of P-gp protein expression in rat liver and kidneys to provide 
insight into the drug transport capacity in these organs at different ages. P-gp protein expression was studied by 
immunocytochemistry and Western blotting in organs from neonatal (age, 1 day), prepubertal (age, 3 weeks), adult 
(age, 3 months), and old (age, 2 years) male and female Wistar rats. In both sexes, the liver P-gp expression pattern 
was: neonatal (highest) > prepubertal > adult < old. In the kidneys, the P-gp expression exhibited the pattern: 
neonatal < prepubertal < adult (highest) > old. Better knowledge of the ontogeny of P-gp expression may improve 
experimental design and the interpretation of results of toxicity studies in juvenile animals as well as the understanding 
of drug toxicity in different age groups in translational studies.
KEY WORDS: age differences; immunocytochemistry; kidney; liver; Mdr1; proximal tubule; P-gp; Western blotting
Importance of transporters in the prediction of drug efficacy and  
adverse events
Nada Božina, Mila Lovrić, and Lana Ganoci
Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb University School of Medicine, 
Zagreb, Croatia
An important role of drug transporters in modulating pharmacokinetic and pharmacodynamic properties has been 
documented for many drugs. Many studies have investigated the association between gene polymorphisms of the efflux 
transporters belonging to the ATP-binding cassette (ABC) superfamily of membrane proteins, as well as of influx 
transporters of the SLC superfamily, and therapy response and clinical outcomes. Convincing results have been obtained 
for ABCB1 gene variants and variability of therapy by digoxin, HIV protease inhibitors, some antiepileptics, antidepressants, 
antipsychotics, immunosuppressants; ABCC2 and mycophenolic acid, anticancer drugs like methotrexate, cisplatin, 
irinotecan, antibiotics; ABCG2 and anticancer drugs, statins, alopurinol, cimetidin, and lamotrigin. Drug-drug interactions 
on the level of variable drug metabolism by phase I and phase II enzymes and drug transporters often called for a phase 
III modulate at many barrier tissues – such as the intestine, liver, blood-brain barrier, kidney, placenta – plasma and 
cerebrospinal fluid drug concentrations that can lead to non-responsiveness, resistance or serious or even lethal adverse 
drug reactions. The most prominent case is the development of rhabdomyolysis due to statin therapy in case of variant/
ineffective allele carriers of SLCO1B1 521C>T with an aggravating role of ABCG2 421C>A and some CYP450 gene 
polymorphisms. Data also emphasize the role of ABCB1 and ABCG2 polymorphisms as promising predictors of the 
clinical outcome of tyrosine kinase inhibitor (TKI) therapy with drugs like imatinib, nilotinib, and sunitinib. Based on 
clinical evidence of drug transporter-mediated drug-drug interactions (DDIs) and some functional polymorphisms affecting 
drug efficacy and safety, both the US Food and Drug Administration and European Medicines Agency recommend 
preclinical evaluation and, when appropriate, clinical assessment of transporter-mediated DDIs. Although variability of 
bioavailability and drug response may be attributed to certain polymorphisms in transporter genes, transcriptional regulation 
or post-transcriptional modification in certain cases seems to be even more critical.
KEY WORDS: adverse drug reactions; drug bioavailability; drug-drug interaction; drug transporters; genetic 
polymorphism
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Functional and structural characterization of organic cation transporter 1 (Oct1) in 
zebrafish (Danio rerio)
Ivan Mihaljević1, Marta Popović1, 3, Roko Žaja1, 4, Nikola Maraković2, and Tvrtko Smital1
Laboratory for Molecular Ecotoxicology, Division for Marine and Environmental Research, Rudjer Boskovic 
Institute1, Biochemistry and Organic Analytical Chemistry Unit, Institute for Medical Research and Occupational 
Health2, Zagreb, Croatia; Department of Oncology3, Sir William Dunn School of Pathology4, University of Oxford, 
Oxford, United Kingdom
Organic cation transporters (OCTs) are members of the SLC22 family within the SLC (Solute Carriers) superfamily 
of membrane proteins. These transporters are responsible for the uptake of numerous organic cations and neutral 
molecules, alongside other inorganic ions. There are three OCTs in humans, two of which play crucial roles in 
ADME (administration, distribution, metabolism and excretion) processes, with high expression of OCT1 in liver 
and OCT2 in kidneys. In zebrafish, an important vertebrate model organism, there are two Oct members, with Oct1 
dominantly expressed in kidneys and livers, where it potentially has the compensatory role of human OCT1 and 
OCT2, whereas Oct2 showed lower expression in toxicologically less relevant tissues, which indicates its potentially 
more specific physiological role. Using transiently transfected human embryonic kidney cells (HEK239) as a 
heterologous expression system, we developed an in vitro tool for the functional analysis of Oct1 by measuring the 
uptake of five identified fluorescent substrates of Oct1. Functional analysis revealed the interaction of Oct1 with 
numerous endo- and xenobiotics. Steroid hormones showed potent inhibition of 4-(4-(dimethylamino)styryl)- 
N-methylpyridinium iodide (ASP+) uptake by Oct1, with Ki values in low micromolar range, along with potent 
interactions with numerous xenobiotics ranging from various pharmaceuticals to deleterious environmental 
contaminants such as organotin compounds. However, further analysis focused on the type of interaction with the 
identified interactors was limited due to the complexity of the Oct1 active site, which we characterized in more 
detail using homology modelling and molecular docking analysis. The structural models of zebrafish Oct1 and 
human OCT1 and OCT2 revealed a characteristic transmembrane organization of proteins and spacious active 
regions with several binding sites. Our research offers novel insight into the function and transport mechanism of 
Oct1 as a potentially crucial factor in steroid hormone homeostasis and toxicological response in zebrafish.
KEY WORDS: functional characterization; organic cation transporters; physiological and xenobiotic interactors; 
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Identification of xenobiotic interactors with multidrug and toxin extrusion (MATE/
SLC47) proteins in zebrafish (Danio rerio)
Jovica Lončar1, Petra Krznar2,3, Marta Popović1,5, Roko Žaja1,4, and Tvrtko Smital1
Laboratory for Molecular Ecotoxicology, Division for Marine and Environmental Research, Rudjer Boskovic 
Institute1, Department for Biology, Faculty of Science, University of Zagreb2, Zagreb, Croatia; Institute of Molecular 
Systems Biology, Department of Biology, ETH Zürich, Zürich, Switzerland3; Sir William Dunn School of Pathology4, 
Department of Oncology5, University of Oxford, Oxford, United Kingdom
Multidrug and toxin extrusion (MATE) proteins are involved in the extrusion of endo- and xenobiotics across the 
plasma membrane, similar to the ATP-binding cassette (ABC) transporters but without the consumption of ATP. 
MATEs are conserved from bacteria to mammals with a differing number of genes within groups. In humans, three 
MATEs have been found (MATE1, 2, and 2k), whereas in zebrafish (Danio rerio), we have found six members 
annotated as DrMate 3-8 which form a distinct cluster separated from the tetrapod MATEs. Tissue expression 
profiling showed a high expression of zebrafish MATEs in toxicologically important tissues, kidney and liver, as 
well as in the testes. MATEs transport activity was analysed in transiently overexpressing HEK293 cell system 
measuring the uptake of model cationic fluorescent dyes. Assay conditions were optimised so that the protein 
interaction with a battery of toxicologically interesting endo- and xeno-biotics could be evaluated. Basic kinetic 
parameters together with the type of interaction – whether a compound is transported or if it merely inhibits the 
transport activity – were determined for over 20 selected physiological and/or xenobiotic interactors of mammalian 
MATEs, including hormones, bile salts, drugs, and pesticides.
KEY WORDS: efflux transporters; MATEs; physiological and xenobiotic interactors; zebrafish
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Invasive vs. native bivalves - differences in tolerance to anthropogenic stress
Ivana Bošnjak1,3, Ana Bielen1, Martina Jaklič4, Marija Cvitanić2, Kristina Sepčić5, Tatjana Simčič4,  
Jasna Lajtner2, and Sandra Hudina2
Department of Biochemical Engineering, Faculty of Food Technology and Biotechnology1, Department of Zoology2, 
Department of Botany3, Faculty of Science, University of Zagreb, Zagreb, Croatia, National Institute of Biology4, 
Department of Biology, Biotehnical Faculty, University of Ljubljana5, Ljubljana, Slovenia
Tolerance towards environmental stress has been frequently considered as one of the key determinants of invasion success. 
However, empirical evidence supporting the assumption that invasive species endure unfavourable conditions better 
compared to native species is limited and has even yielded opposing results. We examined tolerance to thermal stress and 
heavy metal zinc pollution (ZnCl2) in two phylogenetically related and functionally similar freshwater bivalve species; 
the native Anodonta anatina and the invasive Sinanodonta woodiana. We assessed their response to stress using several 
cellular response assays: metabolic rates (ETS - electron transport system), efficiency of the multixenobiotic resistance 
(MXR) mechanism activity, and enzymatic biomarkers (ChE - cholinesterase, GST - glutathione-S-transferase and CAT 
- catalase). Overall, S. woodiana coped with unfavourable conditions much better. This was evident from (i) a significantly 
more pronounced MXR mechanism activity; (ii) significantly higher ETS activity, and (iii) lower response of stress-related 
enzymes (ChE, GST and CAT) under thermal stress and ZnCl2 pollution. The overall better tolerance to thermal extremes 
is an especially important physiological advantage for the future of invasion success of S. woodiana in European freshwaters, 
especially in the context of climate change.
KEY WORDS: freshwater mussels; heavy metal zinc pollution; invasion success; metabolic rate; MXR mechanism 
activity; thermal stress
Interactions of secondary metabolites from cyanobacteria and invasive tropical algae 
with phase 0 membrane transporters in zebrafish (Danio rerio)
Petra Marić, Ivan Mihaljević, Jovica Lončar, Jelena Dragojević, and Tvrtko Smital
Laboratory for Molecular Ecotoxicology, Division for Marine and Environmental Research, Rudjer Boskovic Institute, 
Zagreb, Croatia
One advantageous feature of cyanobacteria and invasive tropical algae from the genus Caulerpa is their ability to produce 
secondary metabolites with diverse biological activities. Some secondary metabolites are toxic and thus represent a 
significant threat to the environment and animal/human health, especially during periods of intensive blooms. So far, the 
understanding of their interaction with membrane transporters involved in the cellular defence mechanism has been poor. 
Therefore, the main goal our study was to determine the interactions of secondary metabolites from C. racemosa, C. 
taxifolia and selected cyanobacterial strains, including genera Anabaena, Nostoc, Phormidium and Oscillatoria, with the 
phase 0 membrane transporters involved in the cellular detoxification mechanism of an important model vertebrate species, 
the zebrafish (Danio rerio). The toxic inhibitory effects of secondary metabolites from Caulerpa and cyanobacterial 
strains to the activity of zebrafish anion (DrOatp1d1) and cation (DrOct1) uptake transporter were determined using the 
human embryonic kidney (HEK293) expression system. In addition, we performed a preliminary identification of the 
biologically active substances that cause the observed toxic effects using the effects-directed analyses (EDA) approach. 
Significant toxicity for these complex biological samples towards toxicologically relevant zebrafish uptake transporters 
DrOatp1d1 and DrOct1 was determined. Caulerpin (CLP) was determined as the major metabolite in C. racemosa while 
caulerpenyne (CYN) appeared to be the dominant biologically active compound in C. taxifolia. CYN was confirmed as 
an inhibitor of the DrOatp1d1 anion transporter. Finally, aquatic cyanobacterial strains, especially the Oscillatoria strain, 
showed the most significant and potentially (eco)toxicologically highly relevant inhibitory effects towards the transport 
activity of DrOatp1d1 and DrOct1 transporters.
KEY WORDS: cellular detoxification; cyanobacteria; invasive tropical algae; phase 0 membrane transporters; secondary 
metabolites; zebrafish (Danio rerio)
